Utsav Nandi, MD

Utsav Nandi, MD

Associate Professor

Department:
SOM-Emergency Medicine

Email:
unandi@umc.edu

Work Phone:
(601) 815-2756

Sponsored Program Funding

Extramural, A 52-week, randomised, double-blind, double-dummy, parallel group, multi-centre, non-inferiority study assessing exacerbation rate, additional measures of asthma control and safety in adult and adolescent severe asthmatic participants with an eosinophilic phenotype treated with GSK3511294 compared with mepolizumab or benralizumab, GlaxoSmithKline Research & Development Limited06/2022 - Present
Extramural, NIH RECOVER (Researching COVID to Enhance Recovery): A Multi-site Observational Study of Post-Acute Sequelae of SARS-CoV-2 Infection in Adults, NHLBI, NINDS09/2021 - Present
Extramural, A Phase 1a study evaluating the safety, tolerability and preliminary efficacy of IBI322 in subjects with advanced malignant tumors, Innovent Biologics (Suzhou) Co. Ltd09/2021 - Present
Extramural, Novel Experimental COVID Therapies Affecting Host Response (NECTAR) Trial, NHLBI-CONNECTS08/2021 - Present
Extramural, STORK program, Kellogg Foundation06/2021 - 05/2023
Extramural, Study of four-factor prothrombin complex concentrate, OCTAPLEX, in patients with acute major bleeding on direct oral anticoagulant (DOAC) therapy with factor Xa inhibitor, Octapharma05/2021 - Present
Extramural, Prevalence of Pathogens in Synovial Fluid Obtained From Emergency Department Patients and Clinical and Laboratory Features of Patients Diagnosed with Septic Arthritis, CDC, Biofire04/2021 - Present
Extramural, Preventing Emerging Infections Through Vaccine Effectiveness Testing – COVID (Project PREVENT), CDC02/2021 - 06/2022
Extramural, A Multicenter, Adaptive, Randomized Controlled Platform Trial of the Safety and Efficacy of Antithrombotic Strategies in Hospitalized Adults with COVID-19 (ACTIV-4 ACUTE), NHLBI, NINDS, BARDA, HHS11/2020 - Present
Extramural, Randomized Master Protocol for Immune Modulators for Treating COVID-19 (ACTIV-1 IM), BARDA, NCATS11/2020 - Present
Extramural, Becton Dickinson Program for Collection of Biospecimens, Becton Dickinson & Company10/2020 - 02/2021
Extramural, A Multicenter, Adaptive, Randomized, Blinded Controlled Trial of the Safety and Efficacy of Investigational Therapeutics for Hospitalized Patients with COVID-19, NIAID10/2020 - Present
Extramural, A phase 2/3, Randomized, Placebo-Controlled, Double-Blind Clinical Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of MK-4482 in Hospitalized Adults with COVID-19, Merck Sharp & Dohme Corp.10/2020 - 08/2021
Extramural, A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Assessing the Efficacy and Safety of Anti-Spike SARS-CoV-2 Monoclonal Antibodies in Preventing SARS-CoV-2 Infection in Household Contacts of Individuals Infected With SARS-CoV-2, Regeneron Pharmaceuticals10/2020 - 08/2021
Extramural, Clinical Evaluation of the BinaxNOW COVID-19 Ag Card in an Asymptomatic Patient Population, Abbott Diagnostics Scarborough, Inc.09/2020 - 07/2021
Extramural, Passive Immunity Trial for Our Nation, NCATS09/2020 - 08/2021
Extramural, An International Multicenter, Randomized, Double-blind, Placebo-controlled, Phase III Study Evaluating the Efficacy and Safety of Dapagliflozin in Respiratory Failure in Patients with COVID-19, Astra Zeneca, St. Luke’s Health System09/2020 - 07/2021
Extramural, Trial of Early Therapies During Non-Hospitalized Outpatient Window for COVID-19 (TREAT NOW), AbbVie, Inc.09/2020 - Present
Extramural, A Master Protocol Assessing the Safety, Tolerability, and Efficacy of Anti-Spike (S) SARS-COV-2 Monoclonal Antibodies for the Treatment of Ambulatory Patients with Covid-19, Regeneron Pharmaceuticals09/2020 - Present
Extramural, A Phase 2, Multicenter, Double-blind, Randomized, Placebo-controlled Study to Evaluate CSL312 in Coronavirus Disease 2019 (COVID-19), CSL Behring08/2020 - 02/2021
Extramural, A Phase 1b/2, Randomized, Double-blind, Placebo-controlled, Multi-center Study to Evaluate the Safety and Efficacy of TJ003234 in Subjects with Severe Coronavirus Disease 2019 (COVID-19), I-Mab Biopharma Co. Ltd.07/2020 - 06/2021
Extramural, Clinical Evaluation of the BinaxNOW COVID-19 Antigen Card, Abbott Diagnostic Scarborough, Inc05/2020 - 05/2021
Extramural, COVID Evaluation of Risk for Emergency Departments (COVERED), CDC05/2020 - 06/2021
Extramural, PETAL Repository of Electronic Data COVID-19 Observational Study (RED CORAL), NHLBI04/2020 - 04/2021
Extramural, Biology and Longitudinal Epidemiology of PETAL COVID-19 Observational Study (BLUE CORAL), NHLBI04/2020 - 04/2021
Intramural, An Open Label Trial of Transfusion of COVID-19 Convalescent Plasma (CCP) to Patients with Moderate to Severe COVID-19, UMMC COVID Research Fund04/2020 - Present
Extramural, Randomized Controlled Trial of Losartan for Inpatients with COVID-19 (ALPS-COVID), Bill and Melinda Gates Foundation04/2020 - 03/2021
Extramural, Outcomes Related to COVID-19 Treated with Hydroxychloroquine among In-patients with Symptomatic Disease (ORCHID), NHLBI04/2020 - 07/2020
Extramural, Management of Diverticulitis in the Emergency Department, CDC08/2019 - Present
Extramural, Monotherapy anticoagulation to expedite home treatment of venous thromboembolism (MATH VTE), Bristol-Myers Squibb Company06/2018 - 08/2020
Extramural, Using Short Stay Units Instead of Routine Admission to Improve Patient Centered Health Outcomes for AHF Patients, AHRQ06/2018 - Present
Extramural, Crystalloid Liberal or Vasopressors Early Resuscitation in Sepsis (CLOVERS), NHLBI06/2018 - Present
Extramural, Prevalence of Extended Spectrum Beta-Lactamase and Carbapenem-Resistant Gram-Negative Bacteria in Patients with Urinary Tract Infection and Urosepsis Admitted through Emergency Departments in the United States, CDC12/2017 - 01/2021
Extramural, Developing syndecan-1 as a biomarker to identify sepsis patients at risk from excessive fluid resuscitation, EMF06/2016 - 06/2018
Extramural, Rapid Administration of Carnitine in Sepsis, NIGMS06/2012 - 05/2017

Publications

Case Report

1Mussarat A, Mussarat N, Nandi U Ruptured ectopic in a heterotopic pregnancy Accepted at JMSMA2023

Journal Article

National Heart, Lung, and Blood Institute Prevention and Early Treatment of Acute Lung Injury Clinical Trials Network (including Nandi U); Shapiro NI, Douglas IS, Brower RG, Brown SM, Exline MC, Ginde AA, Gong MN, Grissom CK, Hayden D, Hough CL, Huang W, Iwashyna TJ, Jones AE, Khan A, Lai P, Liu KD, Miller CD, Oldmixon K, Park PK, Rice TW, Ringwood N, Semler MW, Steingrub JS, Talmor D, Thompson BT, Yealy DM, Self WH. Early Restrictive or Liberal Fluid Management for Sepsis-Induced Hypotension N Engl J Med. 2023;388(6):499-510.2023
Mohr NM, Plumb ID, Harland KK, Pilishvili T, Fleming-Dutra KE, Krishnadasan A, Hoth KF, Saydah SH, Mankoff Z, Haran JP, Briggs-Hagen M, León ES, Talan DA; Project PREVENT Network (including Nandi U) Presence of symptoms 6 weeks after COVID-19 among vaccinated and unvaccinated US healthcare personnel: a prospective cohort study BMJ open, 13(2), e0631412023
Admon AJ, Iwashyna TJ, Kamphuis LA, Gundel SJ, Sahetya SK, Peltan ID, Chang SY, Han JH, Vranas KC, Mayer KP, Hope AA, Jolley SE, Caldwell E, Monahan ML, Hauschildt K, Brown SM, Aggarwal NR, Thompson BT, Hough CL; National Heart, Lung, and Blood Institute PETAL Network (including Nandi U) Assessment of Symptom, Disability, and Financial Trajectories in Patients Hospitalized for COVID-19 at 6 Months. JAMA network open, 6(2), e22557952023
ACTIV-3/TICO Study Group (including Nandi U); Rogers AJ, Wentworth D, Phillips A, Shaw-Saliba K, Dewar RL, Aggarwal NR, Babiker AG, Chang W, Dharan NJ, Davey VJ, Higgs ES, Gerry N, Ginde AA, Hayanga JWA, Highbarger H, Highbarger JL, Jain MK, Kan V, Kim K, Lallemand P, Leshnower BG, Lutaakome JK, Matthews G, Mourad A, Mylonakis E, Natarajan V, Padilla ML, Pandit LM, Paredes R, Pett S, Ramachandruni S, Rehman MT, Sherman BT, Files DC, Brown SM, Matthay MA, Thompson BT, Neaton JD, Lane HC, Lundgren JD. The Association of Baseline Plasma SARS-CoV-2 Nucleocapsid Antigen Level and Outcomes in Patients Hospitalized With COVID-19 Ann Intern Med. 2022;175(10):1401-1410.2022
Mohr, N. M., Krishnadasan, A., Harland, K. K., Ten Eyck, P., Mower, W. R., Schrading, W. A., Montoy, J., McDonald, L. C., Kutty, P. K., Hesse, E., Santibanez, S., Weissman, D. N., Slev, P., Talan, D. A., & Project COVERED Emergency Department Network (including Nandi, U.) Emergency department personnel patient care-related COVID-19 risk PloS one, 17(7), e02715972022
Valley TS, Schutz A, Peltan ID, Vranas KC, Mathews KS, Jolley SE, Palakshappa JA, Hough CL; National Heart, Lung, and Blood Institute Clinical Trials Network for the Prevention and Early Treatment of Acute Lung Injury (PETAL) (including Nandi U). Organization of Outpatient Care After COVID-19 Hospitalization. Chest. 2022 Jun;161(6):1485-1489.2022
ACTIV-3/Therapeutics for Inpatients with COVID-19 (TICO) Study Group (including Nandi U). Efficacy and safety of two neutralising monoclonal antibody therapies, sotrovimab and BRII-196 plus BRII-198, for adults hospitalised with COVID-19 (TICO): a randomised controlled trial. Lancet Infect Dis. 2022 May;22(5):622-635. doi: 10.1016/S1473-3099(21)00751-9.2021
ACTIV-3/TICO Bamlanivimab Study Group (including Nandi U), Lundgren JD, …Neaton JD. Responses to a Neutralizing Monoclonal Antibody for Hospitalized Patients With COVID-19 According to Baseline Antibody and Antigen Levels : A Randomized Controlled Trial. Ann Intern Med. 2022 Feb;175(2):234-243.2021
Pilishvili T, Gierke R, Fleming-Dutra KE, Farrar JL, Mohr NM, Talan DA, Krishnadasan A, Harland KK, Smithline HA, Hou PC, Lee LC, Lim SC, Moran GJ, Krebs E, Steele MT, Beiser DG, Faine B, Haran JP, Nandi U, Schrading WA, Chinnock B, Henning DJ, Lovecchio F, Lee J, Barter D, Brackney M, Fridkin SK, Marceaux-Galli K, Lim S, Phipps EC, Dumyati G, Pierce R, Markus TM, Anderson DJ, Debes AK, Lin MY, Mayer J, Kwon JH, Safdar N, Fischer M, Singleton R, Chea N, Magill SS, Verani JR, Schrag SJ; Vaccine Effectiveness among Healthcare Personnel Study Team. Effectiveness of mRNA Covid-19 Vaccine among U.S. Health Care Personnel N Engl J Med. 2021 Dec 16;385(25):e90.2021
Weinreich DM, Sivapalasingam S, Norton T, Ali S, Gao H, Bhore R, Xiao J, Hooper AT, Hamilton JD, Musser BJ, Rofail D, Hussein M, Im J, Atmodjo DY, Perry C, Pan C, Mahmood A, Hosain R, Davis JD, Turner KC, Baum A, Kyratsous CA, Kim Y, Cook A, Kampman W, Roque-Guerrero L, Acloque G, Aazami H, Cannon K, Simón-Campos JA, Bocchini JA, Kowal B, DiCioccio AT, Soo Y, Geba GP, Stahl N, Lipsich L, Braunstein N, Herman G, Yancopoulos GD; Trial Investigators (including Nandi U). REGEN-COV Antibody Combination and Outcomes in Outpatients with Covid-19. N Engl J Med. 2021 Dec 2;385(23):e81.2021
REMAP-CAP Investigators; ACTIV-4a Investigators (including Nandi U); ATTACC Investigators, Goligher EC, …Zarychanski R. Therapeutic Anticoagulation with Heparin in Critically Ill Patients with Covid-19. N Engl J Med. 2021 Aug 26;385(9):777-789.2021
ATTACC Investigators; ACTIV-4a Investigators (including Nandi U); REMAP-CAP Investigators, Lawler PR, …Zarychanski R. Therapeutic Anticoagulation with Heparin in Noncritically Ill Patients with Covid-19. N Engl J Med. 2021 Aug 26;385(9):790-802.2021
Puskarich MA, Jennaro TS, Gillies CE, Evans CR, Karnovsky A, McHugh CE, Flott TL, Jones AE, Stringer KA; RACE Investigators (including Nandi U). Pharmacometabolomics identifies candidate predictor metabolites of an L-carnitine treatment mortality benefit in septic shock. Clin Transl Sci. 2021 Nov;14(6):2288-2299.2021
Mathews KS, Seitz KP, Vranas KC, Duggal A, Valley TS, Zhao B, Gundel S, Harhay MO, Chang SY, Hough CL; National Heart, Lung, and Blood Institute Prevention and Early Treatment of Acute Lung Injury (PETAL) Clinical Trials Network (including Nandi U). Variation in Initial U.S. Hospital Responses to the Coronavirus Disease 2019 Pandemic. Crit Care Med. 2021 Jul 1;49(7):1038-1048.2021
Nandi U, Jones AE, Puskarich MA. Group IIA secretory phospholipase 2 independently predicts mortality and positive blood culture in emergency department sepsis patients. J Am Coll Emerg Physicians Open. 2021 Jun 18;2(3):e12460.2021
Mussarat, A., Rouhan, J., & Nandi, U. Diagnosing posterior vitreous detachment in the emergency department by point of care ultrasound detection of a Weiss ring. Visual Journal of Emergency Medicine. Volume 23, 2021.2021
Pilishvili T, Fleming-Dutra KE, Farrar JL, Gierke R, Mohr NM, Talan DA, Krishnadasan A, Harland KK, Smithline HA, Hou PC, Lee LC, Lim SC, Moran GJ, Krebs E, Steele M, Beiser DG, Faine B, Haran JP, Nandi U, Schrading WA, Chinnock B, Henning DJ, LoVecchio F, Nadle J, Barter D, Brackney M, Britton A, Marceaux-Galli K, Lim S, Phipps EC, Dumyati G, Pierce R, Markus TM, Anderson DJ, Debes AK, Lin M, Mayer J, Babcock HM, Safdar N, Fischer M, Singleton R, Chea N, Magill SS, Verani J, Schrag S; Vaccine Effectiveness Among Healthcare Personnel Study Team. Interim Estimates of Vaccine Effectiveness of Pfizer-BioNTech and Moderna COVID-19 Vaccines Among Health Care Personnel - 33 U.S. Sites, January-March 2021. MMWR Morb Mortal Wkly Rep. 2021 May 21;70(20):753-758.2021
Schrading WA, Trent SA, Paxton JH, Rodriguez RM, Swanson MB, Mohr NM, Talan DA; Project COVERED Emergency Department Network (including Nandi U). Vaccination rates and acceptance of SARS-CoV-2 vaccination among U.S. emergency department health care personnel. Acad Emerg Med. 2021 Apr;28(4):455-458.2021
Rodriguez RM, Montoy JCC, Hoth KF, Talan DA, Harland KK, Eyck PT, Mower W, Krishnadasan A, Santibanez S, Mohr N; Project COVERED Emergency Department Network (including Nandi U). Symptoms of Anxiety, Burnout, and PTSD and the Mitigation Effect of Serologic Testing in Emergency Department Personnel During the COVID-19 Pandemic. Ann Emerg Med. 2021 Jul;78(1):35-43.e2.2021
ACTIV-3/TICO LY-CoV555 Study Group (Nandi U), Lundgren JD, …Neaton JD. A Neutralizing Monoclonal Antibody for Hospitalized Patients with Covid-19. N Engl J Med. 2021 Mar 11;384(10):905-914.2020
Mohr NM, Harland KK, Krishnadasan A, Eyck PT, Mower WR, Willey J, Chisolm-Straker M, Lim SC, McDonald LC, Kutty PK, Hesse E, Santibanez S, Talan DA; Project COVERED Emergency Department Network (including Nandi U). Diagnosed and Undiagnosed COVID-19 in US Emergency Department Health Care Personnel: A Cross-sectional Analysis. Ann Emerg Med. 2021 Jul;78(1):27-34.2020
Self WH, Semler MW, Leither LM, Casey JD, Angus DC, Brower RG, Chang SY, Collins SP, Eppensteiner JC, Filbin MR, Files DC, Gibbs KW, Ginde AA, Gong MN, Harrell FE Jr, Hayden DL, Hough CL, Johnson NJ, Khan A, Lindsell CJ, Matthay MA, Moss M, Park PK, Rice TW, Robinson BRH, Schoenfeld DA, Shapiro NI, Steingrub JS, Ulysse CA, Weissman A, Yealy DM, Thompson BT, Brown SM; National Heart, Lung, and Blood Institute PETAL Clinical Trials Network (including Nandi U). Effect of Hydroxychloroquine on Clinical Status at 14 Days in Hospitalized Patients With COVID-19: A Randomized Clinical Trial. JAMA. 2020 Dec 1;324(21):2165-2176.2020
Garla, V. V., Nandi, U., Vejella, S., & Lien, L.F. COVID-19 and Diabetes Mellitus: The UMMC Experience. Journal of the Mississippi State Medical Association. Vol 61, No. 11/12, 2020.2020
Jones AE, Puskarich MA, Shapiro NI, Guirgis FW, Runyon M, Adams JY, Sherwin R, Arnold R, Roberts BW, Kurz MC, Wang HE, Kline JA, Courtney DM, Trzeciak S, Sterling SA, Nandi U, Patki D, Viele K. Effect of Levocarnitine vs Placebo as an Adjunctive Treatment for Septic Shock: The Rapid Administration of Carnitine in Sepsis (RACE) Randomized Clinical Trial. JAMA Netw Open. 2018 Dec 7;1(8):e186076. doi: 10.1001/jamanetworkopen.2018.6076.2018
Puskarich MA, Nandi U, Long BG, Jones AE. Association between persistent tachycardia and tachypnea and in-hospital mortality among non-hypotensive emergency department patients admitted to the hospital. Clin Exp Emerg Med. 2017 Mar 30;4(1):2-9.2017
Puskarich MA, Cornelius DC, Tharp J, Nandi U, Jones AE. Plasma syndecan-1 levels identify a cohort of patients with severe sepsis at high risk for intubation after large-volume intravenous fluid resuscitation. J Crit Care. 2016 Dec;36:125-129.2016
Puskarich MA, Nandi U, Shapiro NI, Trzeciak S, Kline JA, Jones AE. Detection of microRNAs in patients with sepsis. Journal of Acute Disease, 4(2), 101-106.2015

Review Article

Nandi U, Alam S Medicaid expansion in Mississippi: Are we there yet? Journal of the Mississippi State Medical Association. 2022; 63(4): 83–902022

Book

Weber, A. S., Nandi, U. and Alam, S. An exploration of literature and medicine. Weill Cornell Medical College in Qatar; 2007.2007

Editorial Commentary

Nandi U, Alam S, Dobbs TD Reflections on population health Accepted at JMSMA2023
Nandi U, Puskarich MA, Jones AE. Big data to the rescue of systemic inflammatory response syndrome: is electronic data mining the way of the future? Ann Transl Med. 2016 Dec;4(23):465.2016